Navigation Links
Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
Date:12/6/2008

d by the disturbance. Primary generalized seizures involve the entire brain from the outset, while partial-onset seizures begin in a focal area of the cerebral cortex. In most cases, however, the cause of epilepsy is unknown.

Epilepsy affects more than 50 million people worldwide, including 3 million Americans. Approximately 30 percent of epilepsy patients are not adequately controlled with currently prescribed AEDs.

About GlaxoSmithKline

One of the world's leading research-based pharmaceutical and healthcare companies, GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com.

About Valeant

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com.

     Inquiries:

     GSK US Media inquiries:                Robin Gaitens     (919) 483 2839
                                            Holly Russell     (919) 483 2839

     GSK US Analyst/ Investor inquiries:    Tom Curry         (215) 751 5419

     Valeant Media and Investor inquiries:  Laurie W. Little  (949) 461 6002

GSK cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK'
'/>"/>

SOURCE GlaxoSmithKline; Valeant Pharmaceuticals International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
2. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
3. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
4. Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
5. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
6. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
7. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. New Study: Pine Bark Significantly Reduces Menstrual Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
(Date:9/22/2014)... Sept. 22, 2014  Elusys Therapeutics, Inc. (Elusys), ... infectious disease, today announced it has completed three ... obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development ... from these studies support the safety and tolerability ... the intended therapeutic dose. The conclusion of these ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
(Date:9/22/2014)... NJ. September 22, 2014. Kessler researchers have published ... 10-week psychoeducational wellness program in people with multiple ... overall mental health, perceived stress, and pain. ... for individuals living with MS: Description and outcomes" ... in the International Journal of MS Care ...
(Date:9/22/2014)... News) -- Two new prescription devices approved by the ... relief for people with migraine headaches who don,t tolerate ... One device -- the Cefaly -- is designed to ... -- is meant to be used when migraines first ... have been looking for alternative migraine treatments. Because these ...
(Date:9/22/2014)... Severe weather can occur with little warning, so ... part of National Preparedness Month, Amica Insurance is offering ... the unexpected:, , Build an emergency supply kit. ... one gallon of water per person per day for at least ... that includes pets so your family knows what to do and ...
(Date:9/22/2014)... New York / Westchester County, NY (PRWEB) September 22, ... Plastic Surgery (NYGPS) has joined the Department of Surgery ... The newly named Mount Sinai Doctors New York Group ... and the lower Hudson Valley access to a team ... plastic surgery techniques. Additionally, C. Andrew Salzberg, MD, ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... RIVERWOODS, Ill., June 10 As more and more employees ... a smaller and smaller percentage of them are actually signing ... the findings of the Spencer,s Benefits Reports 2009 ... COBRA in the 2008 plan year at companies covered by ...
... ARLINGTON, Va., June 10 The Generic Pharmaceutical Association ... and CEO Kathleen Jaeger regarding publication of the Federal ... , , "Today,s report from the FTC ... forward on passage of legislation that brings affordable biogenerics ...
... RIVERSIDE, California and NUREMBERG, Germany, June 10 ,Ziehm Imaging ... and Drug,Administration (FDA) has given 510k clearance for the ... RFD, for marketing and,sales within the United States. Designed ... the Ziehm Vision RFD,mobile C-arm combines the latest flat-panel ...
... Corporation (Nasdaq: KNSY ) is scheduled to present ... 18, 2009. , , Joseph W. Kaufmann, Kensey ... at approximately 9:00 a.m. (ET). To hear the live ... . The presentation materials will also be available on ...
... bacteria,s structure, , WEDNESDAY, June 10 (HealthDay News) -- ... a vacation. , Now, researchers have figured out how ... coli, or ETEC -- are able to make ... or "fimbriae" to attach, or bind, to the intestinal ...
... 2009, the Institute for Quality and Efficiency in Health ... assessment of certain newer antidepressants. The project commissioned by ... the benefit of three agents, reboxetine, mirtazapine and bupropion ... German drug approval status. Interested parties and institutions may ...
Cached Medicine News:Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 2Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 3Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 4Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 2Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 3Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 2Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 3Health News:Finding May Lead to Vaccine for Traveler's Diarrhea 2Health News:Preliminary report on antidepressants published 2
... innovative stent allows the physician to intubate the ... with just topical anesthetic drops., ,The SRS is ... in three lengths 25mm, 30mm and 35mm (disposable ... stent is an anchor-shaped head to provide fixation. ...
... or somatomedin-C, is a peptide highly dependent ... promoting activity. IGF-I is transported in serum ... of growth disorders, measurements of IGF-I are ... hormone secretion. A normal plasma or serum ...
... is a high-throughput immunoassay system built around ... 2000 with the important addition of Logic ... to be designed for optimal performance with ... for critical assays such as the cardiac ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
Medicine Products: